key: cord-292611-5os99sve
authors: Lopes, Renato D.; Fanaroff, Alexander C.
title: Anticoagulation in COVID-19: It Is Time for High-Quality Evidence
date: 2020-10-20
journal: J Am Coll Cardiol
DOI: 10.1016/j.jacc.2020.09.008
sha: 
doc_id: 292611
cord_uid: 5os99sve

[Figure: see text]

There are many challenges to conducting randomized controlled trials, especially in the face of a pandemic, but they are necessary to determine whether and how treatments affect outcomes. 

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

Endothelial cell infection and endotheliitis in COVID-19

Evidence-based practical guidance for the antithrombotic management in patients with coronavirus disease (COVID-19) in 2020

COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC State-ofthe-Art Review

Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19

Randomized trials versus common sense and clinical observation: JACC Review Topic of the Week

Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients

Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials

American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients

COVID-19, randomized controlled trials JACC